Business
The BARD1 (ASX:BD1) share price eyes record highs after positive research results
The BARD1 Life Sciences (ASX: BD1) share price is on watch today after positive results from the evaluation of its EXO-NET product in pancreatic cancer.
Let’s take a closer look at the announcement and what this means for the BARD1 share price.
What’s driving the BARD1 share price higher?
BARD1 maintains a cancer diagnostics portfolio. This includes the commercialised hTRET test which is used as a supplement to urine cytology tests. Additionally, the portfolio also includes diagnostics tests in development for ovarian, breast, lung, prostate, and pancreatic cancers. The group is working towards commercialising its…
-
General21 hours agoForget a tariff-induced recession, Australians have been in recession for two years
-
Noosa News22 hours agoQueensland Opposition accuses government of ‘covering up’ Callide Power Station explosion
-
Noosa News21 hours agoMan dies after slamming stolen car into another vehicle on rural Queensland highway
-
Noosa News23 hours agoCameron Hunt assisting police with inquiries after his wife is found dead in suspicious Geham house fire outside of Toowoomba